BioDlink International Company Limited (BioDlink) issued a voluntary announcement addressing recent atypical movements in its share price and volume. The board stated it is unaware of any material adverse developments or inside information that would require disclosure under Hong Kong regulations.

The voluntary general cash offer by WuXi XDC Cayman Inc. (WuXi XDC) was completed in March 2026, and integration of businesses, systems and teams is described as “steady and orderly.”

To accelerate growth, BioDlink signed a conditional CDMO Master Services Agreement with WuXi XDC in May 2026. Under the proposed framework, BioDlink will supply contract development and manufacturing organisation services for bioconjugate drugs and related components over the three financial years ending 31 December 2028. Shareholder approval will be sought at an extraordinary general meeting scheduled for 11 June 2026.

Management expects the agreement to revitalise BioDlink’s existing production capacity, boost utilisation efficiency and create synergies by leveraging WuXi XDC’s global customer network, supply-chain infrastructure, technical expertise and regulatory systems alongside BioDlink’s antibody-drug conjugate (ADC) capabilities.

Industry conditions remain favourable: data presented at the 2026 American Society of Clinical Oncology meeting highlighted breakthrough progress in next-generation ADCs and the first-line approval of ADC + PD-1 combinations, supporting rising outsourcing demand for CDMO services.

BioDlink reiterated its confidence in long-term prospects, committed to ongoing integration efforts and pledged to meet all disclosure obligations. The company also reminded investors to exercise caution when trading its securities.